Compare Johnson Controls International PLC (JCI) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson Controls International PLC vs Revvity Inc — how do they compare? Johnson Controls International PLC trades at $157.91 (market cap $93.28B), while Revvity Inc trades at $155.04 (market cap $16.98B). The key difference: Johnson Controls International PLC is far larger — about 5.5× Revvity Inc's market cap, and Johnson Controls International PLC pays the higher dividend (1.04%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson Controls International PLC for 65 Days and Revvity Inc for 12 Days on average.
| JCI | RVTY | |
|---|---|---|
Market Cap | $93.28B | $16.98B |
Volume | 2,786,476 | 1,456,900 |
Sector | Basic Materials | Health |
52-Week High | $158.76 | $157.36 |
52-Week Low | $105.55 | $82.26 |
Typical Hold Time | 65 Days | 12 Days |
Enterprise Value | $102.12B | $19.30B |
Dividend Yield | 1.04% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson Controls International (JCI) trades at $157.46, up 0.98% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with Q2 2026 EPS beating estimates at $1.42 versus $1.30 expected, and revenue growth accelerating to 9% in Q3 2026. Valuation metrics remain elevated with P/E at 43.38, but profitability is strong with net income margin of 14.32% and ROE of 24.42%.
JCI presents a favorable investment case with consistent earnings beats, raised FY26 guidance, and strong institutional support. Key risks include high valuation multiples and increasing debt-to-asset ratio reaching 26.06% in 2025. The consensus price target of $172.50 suggests 9.6% upside potential from current levels, supported by 28 buy ratings and no sell recommendations from analysts.
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
